PMID- 9027779
OWN - NLM
STAT- MEDLINE
DCOM- 19970519
LR  - 20190512
IS  - 0931-0509 (Print)
IS  - 0931-0509 (Linking)
VI  - 12
IP  - 1
DP  - 1997 Jan
TI  - Effect of treatment with simvastatin on serum cholesteryl ester transfer in 
      patients on dialysis. PERFECT Study Collaborative Group.
PG  - 87-92
AB  - BACKGROUND: Plasma cholesteryl ester transfer activity is increased in patients 
      with chronic renal failure on dialysis who have elevated levels of apolipoprotein 
      B (apoB)-containing lipoproteins. Simvastatin, a 3-hydroxy-3-methylglutaryl 
      coenzyme A (HMG CoA) reductase inhibitor, reduces levels of these lipoproteins 
      but the effect of treatment on cholesteryl ester transfer activity in patients on 
      dialysis remains to be determined. METHODS: We measured serum newly synthesized 
      cholesteryl ester transfer (NCET) activity, lecithin:cholesterol acyltransferase 
      (LCAT) activity and serum lipid, lipoprotein and apolipoprotein concentrations 
      before and immediately after 6 months treatment with simvastatin (10 mg daily, n 
      = 24) or placebo (n = 29) in 53 patients with chronic renal failure receiving 
      haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). RESULTS: 
      Simvastatin therapy significantly reduced serum cholesterol, LDL cholesterol, 
      apoB concentrations, and both NCET (P = 0.001) and LCAT (P = 0.012) rates. The 
      decrease in NCET activity was correlated significantly with the corresponding 
      decrease in apoB concentration (r = 0.715, P < 0.001) and LCAT activity (r = 
      0.715, P < 0.001) during simvastatin therapy and was no longer significant when 
      apoB concentration (P = 0.14) or LCAT activity (P = 0.07) were controlled. 
      CONCLUSIONS: These data show that simvastatin therapy reduces serum NCET rates, 
      and suggest that this may be linked to the concomitant decrease in levels of 
      apoB-containing lipoproteins which are acceptors of transferred cholesteryl 
      esters, and to the decrease in serum LCAT rates in patients with chronic renal 
      failure with treatment.
FAU - Walker, R J
AU  - Walker RJ
AD  - Department of Medicine, University of Otago Medical School, Dunedin, New Zealand.
FAU - Sutherland, W H
AU  - Sutherland WH
FAU - Walker, H L
AU  - Walker HL
FAU - MacMahon, S
AU  - MacMahon S
FAU - Robson, R A
AU  - Robson RA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European 
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
RN  - 0 (Cholesterol Esters)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Lipids)
RN  - 9LHU78OQFD (Lovastatin)
RN  - AGG2FN16EV (Simvastatin)
RN  - EC 2.3.1.26 (Sterol O-Acyltransferase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cholesterol Esters/*blood
MH  - Double-Blind Method
MH  - Enzyme Inhibitors/*pharmacology
MH  - Female
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors
MH  - Kidney Failure, Chronic/blood/drug therapy/therapy
MH  - Lipids/blood
MH  - Lovastatin/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Peritoneal Dialysis, Continuous Ambulatory
MH  - *Renal Dialysis
MH  - Simvastatin
MH  - Sterol O-Acyltransferase/blood
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1093/ndt/12.1.87 [doi]
PST - ppublish
SO  - Nephrol Dial Transplant. 1997 Jan;12(1):87-92. doi: 10.1093/ndt/12.1.87.